Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)
This study has been terminated.
(Due to limited population of research participants.)
Information provided by (Responsible Party):
Jianren Mao, MD, PhD, Massachusetts General Hospital
First received: June 12, 2012
Last updated: February 15, 2017
Last verified: February 2017
The purpose of this study is to see if an FDA-approved drug (Gralise) can help people with certain types of neuropathic pain without causing too many side effects.
Complex Regional Pain Syndrome I (CRPS I)
||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
||Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)
Primary Outcome Measures:
- Visual Analog Scale (VAS) at Visit 3 [ Time Frame: At visit 3 ]
Subjects rated their pain using the VAS at visit 3, which was the last day of their maintenance phase. After this visit, subjects begin to taper the gralise. The VAS is subject reported on a scale of 0-10 with 0 being no pain and 10 being the worst pain they can imagine. Results reported are an average of the 3 subjects who completed visit 3.
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||June 2014 (Final data collection date for primary outcome measure)
Experimental: CRPS I Pain Subjects
This is an open label study that involves taking Gralise pills (gastic-retentive gabapentin) for 8 weeks.
Day 1-15: Titration phase- titrate Gralise from 300 mg/day to 1800 mg/day Day 16-42: Maintenance phase- maintain the dose of 1800 mg/day Day 43-56: Taper phase- taper the Gralise from 100 mg/day to 300 mg/day
Other Name: Gralise
This research is being conducted to see if the drug Gralise can help people with Complex Regional Pain Syndrom Type I (CRPS I) without causing too many side effects. CRPS I is one of the most common conditions of neuropathic pain (pain that results from damage to nerves in the peripheral nervous system). Gralise is approved by the U.S. Food and Drug Administration (FDA) to treat postherpetic neuralgia (a complication of the disease Shingles, which is caused by the chickenpox virus), but is not approved to treat CRPS I.
|Ages Eligible for Study:
||18 Years to 80 Years (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
- Subject will be between 18 to 80 years of age.
- Subject has not been on Gralise.
- Subject has not been on gabapentin for at least one month.
- Subject agrees to make no change in his/her current pain medications during the study period to ensure that comparisons can be made before and after the Gralise treatment.
- Subject has a VAS pain score of 5 or above at the beginning of the study.
- Subject has had CRPS I for at least three months to avoid clinical uncertainty and minimize the study variation.
- Female subjects of childbearing age must have a negative urine pregnancy test at the initial visit.
- Subject has severe liver or renal disease that will affect the elimination of Gralise. (Renal dysfunction is defined as eGFR < 60. Hepatic dysfunction is defined as LFTs ≥ 3X ULN.)
- Subject has pending litigation related to his/her CRPS I condition.
- Subject is pregnant or lactating.
- Subject is allergic to gabapentin or Gralise.
- Subject has a positive urine (illicit) drug test.
- Subject has any history of suicidal thoughts or behaviors, as self reported or in documented medical history.
- Subjects with known seizure disorders (except febrile seizures) and/or taking antiepileptic drugs.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01623271
|Massachusetts General Hospital
|Boston, Massachusetts, United States, 02114 |
Massachusetts General Hospital
||Jianren Mao, M.D., Ph.D.
||Massachusetts General Hospital
||Jianren Mao, MD, PhD, Principal Investigator, Massachusetts General Hospital
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 12, 2012
|Results First Received:
||December 22, 2016
||February 15, 2017
|Individual Participant Data (IPD) Sharing Statement:
|Plan to Share IPD:
Keywords provided by Jianren Mao, MD, PhD, Massachusetts General Hospital:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 20, 2017
Complex Regional Pain Syndromes
Reflex Sympathetic Dystrophy
Autonomic Nervous System Diseases
Nervous System Diseases
Peripheral Nervous System Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents